Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Share-based Compensation (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Share-based Compensation for 8 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 12.7% to -$7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $259000.0 through Dec 2025, up 25800.0% year-over-year, with the annual reading at $259000.0 for FY2025, N/A changed from the prior year.
  • Share-based Compensation for Q4 2025 was -$7.9 million at Precision Biosciences, down from $2.4 million in the prior quarter.
  • The five-year high for Share-based Compensation was $5.1 million in Q2 2022, with the low at -$9.0 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $2.5 million, with a median of $3.4 million recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 31.88% in 2022, then plummeted 404.24% in 2024.
  • Over 5 years, Share-based Compensation stood at $4.4 million in 2021, then grew by 2.28% to $4.5 million in 2022, then plummeted by 34.55% to $3.0 million in 2023, then tumbled by 404.24% to -$9.0 million in 2024, then rose by 12.7% to -$7.9 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at -$7.9 million, $2.4 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.